Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma.
Cancer Immunol Immunother
; 71(11): 2631-2643, 2022 Nov.
Article
in En
| MEDLINE
| ID: mdl-35347395
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Carcinoma, Hepatocellular
/
Liver Neoplasms
Limits:
Humans
Language:
En
Journal:
Cancer Immunol Immunother
Journal subject:
ALERGIA E IMUNOLOGIA
/
NEOPLASIAS
/
TERAPEUTICA
Year:
2022
Document type:
Article
Affiliation country:
Country of publication: